相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Alexander E. Perl et al.
BLOOD (2022)
PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway
Zijia Wang et al.
CELL CYCLE (2022)
Transcriptional activation of Proteasome 26S non-ATPase subunit 7 by forkhead box P3 participates in gastric cancer cell proliferation and apoptosis
Yujie Xu et al.
BIOENGINEERED (2022)
PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells
Xiaoyang Zheng et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)
PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway
Tao Liu et al.
ONCOGENESIS (2022)
A Ubiquitin-Proteasome Gene Signature for Predicting Prognosis in Patients With Lung Adenocarcinoma
Yunliang Tang et al.
FRONTIERS IN GENETICS (2022)
Prognostic Implication and Immunological Role of PSMD2 in Lung Adenocarcinoma
Huihui Zhao et al.
FRONTIERS IN GENETICS (2022)
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia
Rosa G. Lopez-Reyes et al.
FEBS OPEN BIO (2021)
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
Yan Song et al.
BLOOD CANCER JOURNAL (2021)
The Ubiquitin-Proteasome System in Immune Cells
Gonca cetin et al.
BIOMOLECULES (2021)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A. Larson et al.
LEUKEMIA (2021)
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Alfonso E. Bencomo-Alvarez et al.
ONCOGENE (2021)
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
Mike Dennis et al.
BLOOD ADVANCES (2021)
PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma
Yanwen Yang et al.
CELL DEATH DISCOVERY (2021)
Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer
Tzu-Jen Kao et al.
Aging-US (2021)
PSMD9 ribosomal protein network maintains nucleolar architecture and WT p53 levels
Sheikh Burhan Ud Din Farooqee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Safety of FLT3 inhibitors in patients with acute myeloid leukemia
Claudio Cerchione et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy
Andres J. Rubio et al.
CELLS (2021)
PSMC5 Promotes Proliferation and Metastasis of Colorectal Cancer by Activating Epithelial-Mesenchymal Transition Signaling and Modulating Immune Infiltrating Cells
Zirui He et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Deubiquitinase PSMD7 promotes the proliferation, invasion, and cisplatin resistance of gastric cancer cells by stabilizing RAD23B
Jianjiang Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
PSMD7 downregulation suppresses lung cancer progression by regulating the p53 pathway
Xinchun Xu et al.
JOURNAL OF CANCER (2021)
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling
Ruey-Shyang Soong et al.
BMC CANCER (2020)
Epigenetic landscape analysis of lncRNAs in acute myeloid leukemia with DNMT3A mutations
Yu-Jun Dai et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190
Paige Dickson et al.
CELL CHEMICAL BIOLOGY (2020)
Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13
Casey W. Hemmis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma
Yan Song et al.
LEUKEMIA (2019)
Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation
Abdulfattah Salah Fararjeh et al.
CANCERS (2019)
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Yingyao Zhou et al.
NATURE COMMUNICATIONS (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation
Toshiyuki Okumura et al.
JOURNAL OF BIOCHEMISTRY (2018)
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-κB-Mediated Cell Apoptosis
Guang-Yang Yu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
Jianbiao Zhou et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2018)
Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism
Ryan T. VanderLinden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Chang-Xin Shi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets
Xiuxiu Lu et al.
NATURE COMMUNICATIONS (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
(Immuno)proteasomes as therapeutic target in acute leukemia
Jacqueline Cloos et al.
CANCER AND METASTASIS REVIEWS (2017)
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
Clement Larrue et al.
BLOOD (2016)
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma
Y. Song et al.
LEUKEMIA (2016)
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance
Jamshid S. Khorashad et al.
BLOOD (2015)
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
A. M. Eiring et al.
LEUKEMIA (2015)
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Q. Ping Dou et al.
CURRENT CANCER DRUG TARGETS (2014)
A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer
Ravi K. Anchoori et al.
CANCER CELL (2013)
Functions of the 19S complex in proteasomal degradation
Chang-Wei Liu et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Common variations in PSMD3-CSF3 and PLCB4 are associated with neutrophil count
Yukinori Okada et al.
HUMAN MOLECULAR GENETICS (2010)
The proteasome: Overview of structure and functions
Keiji Tanaka
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
K Bagrintseva et al.
BLOOD (2005)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
HJ McKenna et al.
BLOOD (2000)
分享论文
